SERVICES*

Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Subsequent Cardiac and Stroke Events in Patients with Known Vascular Disease Treated with EDTA Chelation Therapy: A Retrospective Study. *

Context: Myocardial infarction (MI) and strokes are leading causes of death in the US. Surgical and medical treatments can be helpful, but carry risks of morbidity and mortality.

Objective: To evaluate whether cardiac events were reduced for patients with known vascular disease who were treated with intravenous ethylene diamine tetra-acetic acid (EDTA) chelation therapy.

Design: Retrospective study with a 3-year follow-up, compared with similar patient groups by use of meta-analysis.

Population and setting: A total of 220 consecutive patients with known vascular disease were treated with chelation therapy during 1992-2001. Eight outpatient centres were included: five from the US and one each from Denmark, the Netherlands and Brazil. Average patient age was 64 years, 72.3% were males and 18.2% were smokers. Average number of treatments was 58.

Main outcome measures: MI, stroke and death from any cause were primary outcome measures. Secondary measures were resolution of symptoms and need for coronary artery bypass surgery (CABG) and percutaneous transluminal coronary angioplasty.

Results: According to the meta-analysis, expected outcomes in a 3-year follow-up period for 220 patients with coronary artery disease treated only with conventional therapies would be 15 MIs and six deaths. There were no deaths and no MIs in this group of patients who received chelation therapy. Four patients had strokes but recovered well. There were two angioplasties and six CABG procedures. Compared with similar patient populations treated with conventional therapies, patients who also were chelated had a 93.6% lesser need for angioplasty and a 62.5% reduced need for CABG. Of the patients that initiated treatment with symptoms, 68.7% had complete resolution of symptoms.

 

* Legal Disclaimer: Chelation and Hyperbaric Therapy, Stem Cell Therapy, and other treatments and modalities mentioned or referred to in this web site are medical techniques that may or may not be considered “mainstream”. As with any medical treatment, results will vary among individuals, and there is no implication or guarantee that you will heal or achieve the same outcome as patients herein.

As with any procedure, there could be pain or other substantial risks involved. These concerns should be discussed with your health care provider prior to any treatment so that you have proper informed consent and understand that there are no guarantees to healing.

THE INFORMATION IN THIS WEBSITE IS OFFERED FOR GENERAL EDUCATIONAL PURPOSES ONLY AND DOES NOT IMPLY OR GIVE MEDICAL ADVICE. No Doctor/Patient relationship shall be deemed to have arisen simply by reading the information contained on these pages, and you should consult with your personal physician/care giver regarding your medical treatment before undergoing any sort of treatment or therapy.

Published on 11-10-2008
Authors: Chappell, L Terry 1; Shukla, Rakesh 2; Yang, Jun 2; Blaha, Rene 3; Born, Tammy 4; Hancke, Claus 5; Mitchell, William 6; Olszewer, Efrain 7; van der Schaar, Peter 8; Ventresco, James 9
Source: Evidence-Based Integrative Medicine. 2(1),:27-35, 2005.